Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Immunogenic death of colon cancer cells treated with oxaliplatin

Abstract

Both the pre-apoptotic exposure of calreticulin (CRT) and the post-apoptotic release of high-mobility group box 1 protein (HMGB1) are required for immunogenic cell death elicited by anthracyclins. Here, we show that both oxaliplatin (OXP) and cisplatin (CDDP) were equally efficient in triggering HMGB1 release. However, OXP, but not CDDP, stimulates pre-apoptotic CRT exposure in a series of murine and human colon cancer cell lines. Subcutaneous injection of OXP-treated colorectal cancer (CRC), CT26, cells induced an anticancer immune response that was reduced by short interfering RNA-mediated depletion of CRT or HMGB1. In contrast, CDDP-treated CT26 cells failed to induce anticancer immunity, unless recombinant CRT protein was absorbed into the cells. CT26 tumors implanted in immunocompetent mice responded to OXP treatment in vivo, and this therapeutic response was lost when CRT exposure by CT26 cells was inhibited or when CT26 cells were implanted in immunodeficient mice. The knockout of toll-like receptor 4 (TLR4), the receptor for HMGB1, also resulted in a deficient immune response against OXP-treated CT26 cells. In patients with advanced (stage IV, Duke D) CRC, who received an OXP-based chemotherapeutic regimen, the loss-of-function allele of TLR4 (Asp299Gly in linkage disequilibrium with Thr399Ile, reducing its affinity for HMGB1) was as prevalent as in the general population. However, patients carrying the TLR4 loss-of-function allele exhibited reduced progression-free and overall survival, as compared with patients carrying the normal TLR4 allele. In conclusion, OXP induces immunogenic death of CRC cells, and this effect determines its therapeutic efficacy in CRC patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Agnese DM, Calvano JE, Hahm SJ, Coyle SM, Corbett SA, Calvano SE et al. (2002). Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 186: 1522–1525.

    Article  CAS  PubMed  Google Scholar 

  • Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R et al. (2007a). The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 220: 47–59.

    Article  CAS  PubMed  Google Scholar 

  • Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A et al. (2007b). Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13: 1050–1059.

    Article  CAS  PubMed  Google Scholar 

  • Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M et al. (2000). TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 25: 187–191.

    Article  CAS  PubMed  Google Scholar 

  • Blachere NE, Darnell RB, Albert ML . (2005). Apoptotic cells deliver processed antigen to dendritic cells for cross-presentation. PLoS Biol 3: e185.

    Article  PubMed  PubMed Central  Google Scholar 

  • Bouché, Castaing M, Etienne PL, Texereau P, Auby D, Bedenne L et al. (2007). Randomized strategical of chemotherapy in metastatic colorectal cancer (FFCD 2000–05): preliminary results. J Clin Oncol 25: 4069.

    Google Scholar 

  • Camus M, Tosolini M, Mlecnik B, Pages F, Kirilovsky A, Berger A et al. (2009). Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res 69: 2685–2693.

    Article  CAS  PubMed  Google Scholar 

  • Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N et al. (2005). Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 202: 1691–1701.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Castedo M, Coquelle A, Vitale I, Vivet S, Mouhamad S, Viaud S et al. (2006). Selective resistance of tetraploid cancer cells against DNA damage-induced apoptosis. Ann NY Acad Sci 1090: 35–49.

    Article  CAS  PubMed  Google Scholar 

  • Ferwerda B, McCall MB, Alonso S, Giamarellos-Bourboulis EJ, Mouktaroudi M, Izagirre N et al. (2007). TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci USA 104: 16645–16650.

    Article  PubMed  PubMed Central  Google Scholar 

  • Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C et al. (2006). Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960–1964.

    Article  CAS  PubMed  Google Scholar 

  • Hsu WM, Hsieh FJ, Jeng YM, Kuo ML, Chen CN, Lai DM et al. (2005). Calreticulin expression in neuroblastoma—a novel independent prognostic factor. Ann Oncol 16: 314–321.

    Article  CAS  PubMed  Google Scholar 

  • Kelland L . (2007). The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7: 573–584.

    Article  CAS  PubMed  Google Scholar 

  • Laane E, Tamm KP, Buentke E, Ito K, Khahariza P, Oscarsson J et al. (2009). Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy. Cell Death Differ.

  • Matzinger P . (2002). The danger model: a renewed sense of self. Science 296: 301–305.

    Article  CAS  PubMed  Google Scholar 

  • Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren GJ . (2008). Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother 57: 197–206.

    Article  CAS  PubMed  Google Scholar 

  • Muggia FM, Fojo T . (2004). Platinums: extending their therapeutic spectrum. J Chemother 16 (Suppl 4): 77–82.

    Article  CAS  PubMed  Google Scholar 

  • Netea-Maier RT, Hunsucker SW, Hoevenaars BM, Helmke SM, Slootweg PJ, Hermus AR et al. (2008). Discovery and validation of protein abundance differences between follicular thyroid neoplasms. Cancer Res 68: 1572–1580.

    Article  CAS  PubMed  Google Scholar 

  • Obeid M, Panaretakis T, Joza N, Tufi R, Tesniere A, van Endert P et al. (2007a). Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 14: 1848–1850.

    Article  CAS  PubMed  Google Scholar 

  • Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL et al. (2007b). Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13: 54–61.

    Article  CAS  PubMed  Google Scholar 

  • Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R et al. (2005). Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353: 2654–2666.

    Article  CAS  PubMed  Google Scholar 

  • Panaretakis T, Joza N, Modjtahedi N, Vitale I, Durchschlag M, Fimia GM et al. (2008). The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ 15: 1499–1509.

    Article  CAS  PubMed  Google Scholar 

  • Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC et al. (2009). Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 28: 578–590.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D et al. (2006). High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 290: C917–C924.

    Article  CAS  PubMed  Google Scholar 

  • Sancho D, Joffre OP, Keller AM, Rogers NC, Martinez D, Hernanz-Falcon P et al. (2009). Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature 458: 899–903.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sancho D, Mourao-Sa D, Joffre OP, Schulz O, Rogers NC, Pennington DJ et al. (2008). Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest 118: 2098–2110.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Savill J, Fadok V . (2000). Corpse clearance defines the meaning of cell death. Nature 407: 784–788.

    Article  CAS  PubMed  Google Scholar 

  • Streit M, Riccardi L, Velasco P, Brown LF, Hawighorst T, Bornstein P et al. (1999). Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci USA 96: 14888–14893.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, Kepp O et al. (2008). Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol 20: 504–511.

    Article  CAS  PubMed  Google Scholar 

  • Toquet C, Jarry A, Bou-Hanna C, Bach K, Denis MG, Mosnier JF et al. (2007). Altered calreticulin expression in human colon cancer: maintenance of calreticulin expression is associated with mucinous differentiation. Oncol Rep 17: 1101–1107.

    CAS  PubMed  Google Scholar 

  • Wang D, Lippard SJ . (2005). Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307–320.

    Article  CAS  PubMed  Google Scholar 

  • Wright CA, Kozik P, Zacharias M, Springer S . (2004). Tapasin and other chaperones: models of the MHC class I loading complex. Biol Chem 385: 763–778.

    Article  CAS  PubMed  Google Scholar 

  • Zeng G, Aldridge ME, Tian X, Seiler D, Zhang X, Jin Y et al. (2006). Dendritic cell surface calreticulin is a receptor for NY-ESO-1: direct interactions between tumor-associated antigen and the innate immune system. J Immunol 177: 3582–3589.

    Article  CAS  PubMed  Google Scholar 

  • Zhang Y, Williams DB . (2006). Assembly of MHC class I molecules within the endoplasmic reticulum. Immunol Res 35: 151–162.

    Article  CAS  PubMed  Google Scholar 

  • Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G . (2008). The anticancer immune response: indispensable for therapeutic success? J Clin Invest 118: 1991–2001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank all the investigators who participated in the FFCD 2000–05 clinical trial; Pierre Laurent Puig for help with DNA extraction and storage; and Patrick Gonin and IGR animal facility for helping with mouse breeding. This study was supported by INSERM (AT); FRM (FS); Cancéropôle Ile-de-France, Institut National du Cancer, Fondation de France, Association Laurette Fugain, Cent pour Sang la Vie, Agence National de la Recherche, Association for International Cancer Research (AICR), and the European Commission (ApoSys, ChemoRes, Death-Train, RIGHT) (GK); la Ligue and FRM (LA); a fellowship from La Ligue (IM); a fellowship from ARC (MM).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to G Kroemer.

Additional information

Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tesniere, A., Schlemmer, F., Boige, V. et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29, 482–491 (2010). https://doi.org/10.1038/onc.2009.356

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2009.356

Keywords

This article is cited by

Search

Quick links